Related Experiment Video

Updated: Jul 19, 2026

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

Pediatric cyanide poisoning: causes, manifestations, management, and unmet needs

Robert J Geller1, Claudia Barthold, Jane A Saiers

  • 1Department of Pediatrics and the Medical Toxicology Fellowship Program, Emory University School of Medicine, Atlanta, Georgia, USA. robert_geller@oz.ped.emory.edu

Pediatrics
|November 3, 2006
PubMed

Insights

Childhood cyanide poisoning is rare but challenging to manage. Hydroxocobalamin may offer a safer alternative antidote for pediatric patients than the current cyanide antidote kit.

Area of Science:

  • Toxicology
  • Pediatric Medicine
  • Emergency Medicine

Background:

  • Childhood cyanide poisoning is uncommon but poses diagnostic and therapeutic challenges for healthcare providers.
  • Potential sources include fire smoke, household toxins, and cyanogenic foods.
  • Pediatric patients may exhibit increased vulnerability to certain cyanide exposure routes.

Purpose of the Study:

  • To review current data on pediatric cyanide poisoning.
  • To discuss sources, clinical manifestations, and treatment strategies.
  • To identify unmet needs in managing this condition in children.

Main Methods:

  • Literature review of existing studies on pediatric cyanide poisoning.
  • Analysis of case reports and clinical data.
  • Evaluation of current and potential antidote efficacy and safety in children.

Main Results:

  • Cyanide poisoning sources and symptoms are similar in children and adults, but pediatric vulnerability varies.
  • The U.S. cyanide antidote kit has risks in children, including excessive methemoglobinemia due to age-related hemoglobin kinetics.
  • Hydroxocobalamin, used in Europe, shows promise as a safer alternative antidote.

Conclusions:

  • Effective management of pediatric cyanide poisoning requires awareness of specific pediatric risks.
  • The current U.S. antidote kit presents safety concerns for children.
  • Hydroxocobalamin represents a potential alternative with an improved risk/benefit profile for pediatric use.

Related Concept Videos

Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...